NeuroMetrix Publishes Study Demonstrating That DPNCheck Diagnoses Diabetic Peripheral Neuropathy
$NURO
Medical/Dental Instruments
Health Care
NeuroMetrix Publishes Study Demonstrating That DPNCheck Diagnoses Diabetic Peripheral Neuropathy
Save time and jump to the most important pieces.
WOBURN, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today reported financial and business highlights for the quarter and six months ended June 30, 2024. The Company's mission is to reduce the impact of neurological disorders and pain syndromes through innovative non-invasive medical devices. In February of this year, the Company announced that it had initiated a review of strategic options with an objective of enhancing shareholder value. Over the past six months, the Company has invested considerable effort in evaluating a number of specific strategic directions and also making financial, operational and commercial optimizations. In collaboration with a fina
WOBURN, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) announced today that it plans to issue its 2024 second quarter business and financial highlights before the opening of the market on August 6, 2024. The Company will host a conference call at 8:00 a.m., Eastern Time on August 6, 2024. For participants who wish to access the Q2 2024 Conference Call live via telephone and be able to ask questions, please register in advance here. Upon registering, a dial-in and unique PIN will be provided on screen and via email to join the call. An audio-only webcast of the call, along with the earnings press release and accompanying condensed financial statements, may be acce
WOBURN, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) announced today that it plans to issue its 2023 fourth quarter and year end business and financial highlights before the opening of the market on February 22, 2024. The Company will host a conference call at 8:00 a.m., Eastern Time on February 22, 2024. For participants who wish to access the Q4 and year end 2023 Conference Call live via telephone and be able to ask questions, please register in advance here. Upon registering, a dial-in and unique PIN will be provided on screen and via email to join the call. An audio-only webcast of the call, along with the earnings press release and accompanying condensed f
4 - NeuroMetrix, Inc. (0001289850) (Issuer)
4 - NeuroMetrix, Inc. (0001289850) (Issuer)
4 - NeuroMetrix, Inc. (0001289850) (Issuer)
Joshua S. Horowitz joins Board of DirectorsAt-the-market equity facility terminated WOBURN, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today announced two steps to enhance shareholder value following feedback and recommendations from one of its largest shareholders, Ephraim Fields of Echo Lake Capital. The Board has approved the appointment of Joshua S. Horowitz as a new independent director with a 1-year term. Mr. Horowitz is a professional investor with over 22 years of investing experience. Since January 2012, he has served as a portfolio manager with Palm Management (US) LLC. Mr. Horowitz also brings extensive public company board experience. Earlie
WOBURN, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that it has appointed Jonathan "Breck" Harmel as National Director of Sales, Neuromodulation. Mr. Harmel will be responsible for leading the sales organization for the Company's prescription wearable neurotherapeutics business in the U.S. market. The Company recently received FDA De Novo authorization to market its Quell® device as an aid for reducing the symptoms of fibromyalgia in adults with high pain sensitivity. The Company received FDA Breakthrough Designation for the use of Quell to treat fibromyalgia in July 2021. Mr. Harmel brings 15 years of experience in high growth medical technol
WOBURN, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today announced the appointment of Bradley M. Fluegel to its Board of Directors, effective as of July 1, 2022. Mr. Fluegel has a broad commercial and advisory background with concentrated industry experience in healthcare and medical technology. He has held numerous leadership roles over the past 25+ years, primarily in healthcare strategy and business development. Most recently, Mr. Fluegel was Senior Vice President, Chief Healthcare Commercial Market Development Officer for Walgreens Co. In this role he was responsible for leading all commercial healthcare activities, including sales and contracting, biopha
SC 13G - NeuroMetrix, Inc. (0001289850) (Subject)
SC 13D/A - NeuroMetrix, Inc. (0001289850) (Subject)
SC 13D - NeuroMetrix, Inc. (0001289850) (Subject)
10-Q - NeuroMetrix, Inc. (0001289850) (Filer)
8-K - NeuroMetrix, Inc. (0001289850) (Filer)
10-Q - NeuroMetrix, Inc. (0001289850) (Filer)
WOBURN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today reported financial and business highlights for the quarter and nine months ended September 30, 2024. The Company develops proprietary non-invasive medical devices for the diagnosis and treatment of pain and neurological disorders. NeuroMetrix, Inc. is actively pursuing its previously announced review of strategic options to enhance shareholder value. Over the past several quarters, the Company has strengthened its Board of Directors, terminated common stock sales under its ATM program, implemented a reduction-in-force, and phased-out its legacy ADVANCE® business. As a result, operating expenses and cash
WOBURN, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today for the purpose of clarity, reiterated that the Company is engaged in a review of strategic alternatives. In February of this year, the Company announced that it had initiated a review of strategic options with an objective of enhancing shareholder value. Over the past 6 months, the Company has invested considerable effort in evaluating a number of specific strategic directions and also making financial, operational and commercial optimizations. In collaboration with a financial advisor, the Company conducted an extensive survey of potential transactions. Detailed diligence was performed on multiple op
WOBURN, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO) today reported financial and business highlights for the quarter and six months ended June 30, 2024. The Company's mission is to reduce the impact of neurological disorders and pain syndromes through innovative non-invasive medical devices. In February of this year, the Company announced that it had initiated a review of strategic options with an objective of enhancing shareholder value. Over the past six months, the Company has invested considerable effort in evaluating a number of specific strategic directions and also making financial, operational and commercial optimizations. In collaboration with a fina
NeuroMetrix (NASDAQ:NURO) reported quarterly losses of $(1.67) per share. This is a 1.83 percent decrease over losses of $(1.64) per share from the same period last year. The company reported $1.09 million in sales this quarter. This is a 36.64 percent decrease over sales of $1.73 million the same period last year.
Gainers Mobile-health Network (NASDAQ:MNDR) shares increased by 34.7% to $27.44 during Friday's regular session. The market value of their outstanding shares is at $932.9 million. NKGen Biotech (NASDAQ:NKGN) stock increased by 19.76% to $1.03. The company's market cap stands at $23.4 million. The company's, Q4 earnings came out 3 days ago. Kintara Therapeutics (NASDAQ:KTRA) stock increased by 18.57% to $0.13. The market value of their outstanding shares is at $4.9 million. NeuroMetrix (NASDAQ:NURO) stock moved upwards by 17.26% to $4.28. The company's market cap stands at $8.5 million. Inspire Veterinary (NASDAQ:IVP) shares moved upwards by 17.24% to $0.05. The company's market cap stan